Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Large Cell, Undifferentiated Or Poorly Differentiated Stage IV Carcinoma of the Lung

Trial Profile

Phase II Study of Antineoplastons A10 and AS2-1 in Patients With Large Cell, Undifferentiated Or Poorly Differentiated Stage IV Carcinoma of the Lung

Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2017

At a glance

  • Drugs Antineoplaston A10/antineoplaston AS2-1 (Primary)
  • Indications Lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Dec 2017 Status changed from active, no longer recruiting to discontinued.
    • 26 Oct 2008 Planned end date changed from 1 Jan 2008 to 1 Dec 2000 as reported by ClinicalTrials.gov.
    • 18 Apr 2008 Status change from recruiting to in progress, according to clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top